Evidence map›Paper›PMID 35519172›Full record

ArticleThe Pan African medical journal2022

Association between human leukocyte antigen class II (HLA-DRB and -DQB) alleles and outcome of exposure to

Susan Odera, Marianne Mureithi, Andrew Aballa, Noel Onyango, Samwel Kazungu, Simon Ogolla, George Kaiyare, Omu Anzala, Julius Oyugi

Open access · goldAbstract read
In one paragraph

Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Susan OderaDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya.
Marianne MureithiDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya.
Andrew AballaDepartment of Medical Laboratory Sciences, School of Medicine, Kenyatta University, Nairobi, Kenya.
Noel OnyangoDepartment of Clinical Medicine and Therapeutics, School of Medicine, University of Nairobi, Nairobi, Kenya.
Samwel KazunguKenya Aids Vaccine Initiative (KAVI) Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.
Simon OgollaKenya Aids Vaccine Initiative (KAVI) Institute of Clinical Research, University of Nairobi, Nairobi, Kenya.
George KaiyareBiozeq Kenya Molecular Laboratory, Nairobi, Kenya.
Omu AnzalaDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya.
Julius OyugiDepartment of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya.
University of Nairobi · KEKenya AIDS Vaccine Initiative · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: human leukocyte antigen (HLA) class II alleles play an important role in the early immune response to tuberculosis (TB) by presenting antigenic peptides to CD4+ T cells, hence polymorphisms in those genes can influence the efficiency of the immune response to infection and progression to active disease. Methods: an analytical cross-sectional study of adult pulmonary tuberculosis (PTB) patients at Mbagathi County Hospital, Nairobi and their HHCs. Sociodemographic data were captured on questionnaires and clinical data extracted from patient files. Intravenous blood samples were drawn for interferon-gamma release assay (IGRA) to determine latent tuberculosis infection (LTBI) among HHCs, and for extraction of DNA used in typing of HLA-DQB1 and HLA-DRB1 alleles by PCR sequence specific primer amplification. Chi-square and Fisher's exact test were used to compare the HLA type II allele frequencies of LTBI negative HHCs, LTBI positive HHCs and active TB patients. Logistic regression was used to adjust for HIV status. Results: the HLA-DQB1 and HLA-DRB1 alleles were analyzed in 17 PTB and 37 HHCs. Nineteen (19) HHCs were LTBI positive, while 18 were LTBI negative. The frequency of DRB3*1 was 0.17-fold lower [95% CI=0.03-0.83] among PTB patients compared to HHCs before adjustment for HIV status (p=0.048). The frequency of the DRB5*2 allele was significantly higher (p=0.013) among PTB patients (23.5%) compared to HHCS (0.00%). After adjusting for HIV status, the frequency of DRB1*14 was 12-fold higher [95% CI=1.11-138.2] among PTB patients compared to HHCs (p=0.040). Conclusion: the higher frequencies of HLA-DRB5*2 and HLA-DRB1*14 alleles in PTB patients suggest a likely association with progression to active PTB. The higher frequency of HLA-DRB3*1 allele among LTBI negative HHCs shows its likely protective role against M. tuberculosis infection in this population.

Indexed as

HIV InfectionsLatent TuberculosisMycobacterium tuberculosisTuberculosis, Lymph NodeTuberculosis, PulmonaryAdultAllelesCross-Sectional StudiesGene FrequencyHLA-DRB1 ChainsHumansKenyaHLA-DRB1 Chainshousehold contactsHuman leucocyte antigenKenyalatent tuberculosispulmonary tuberculosis

Identifiers

PMID35519172
PMCPMC9046861
OpenAlexW4213360367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.